Trials / Recruiting
RecruitingNCT07169851
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 204 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3537021 | Administered SC |
| DRUG | Placebo | Administered SC |
| DRUG | Standard of Care Antiemetic Therapies | 5-HT3 Receptor Antagonist, NK1 Receptor Antagonist, Dexamethasone administered orally, IV, or transdermally |
| DRUG | Background Chemotherapy | Cisplatin or anthraxyline and cyclophosphamide (AC) administered IV |
Timeline
- Start date
- 2025-11-28
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2025-09-12
- Last updated
- 2026-03-20
Locations
67 sites across 10 countries: United States, Australia, China, France, Italy, Japan, Romania, Spain, Taiwan, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07169851. Inclusion in this directory is not an endorsement.